We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

CTI Completes Acquisition of Pacritinib a Highly Selective JAK2 Inhibitor

News   Jun 04, 2012

 
CTI Completes Acquisition of Pacritinib a Highly Selective JAK2 Inhibitor
 
 
 

RELATED ARTICLES

Compound Awakens Cancer Cells’ Self-destruct System

News

Researchers develop a compound that, in mice, awakened cancer cells’ "self-destruct" process, killing the cancer cells and consequently stopping their spread, while leaving "normal" cells untouched.

READ MORE

A Potential New Treatment for Preventing PTSD

News

A team of researchers has identified a protein complex that is elevated in patients with post-traumatic stress disorder (PTSD). The team have designed a peptide to target and interfere with the complex, this interference could help treat symptoms of the disorder.

READ MORE

Gene Therapy for Life-limiting Blood Disorder Becomes Commercially Available

News

bluebird bio Inc. have announced that their gene therapy for the blood disorder transfusion-dependent β-thalassemia (TDT) is commercially available for the first time.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE